PubMed Citations for id: 6918554

Year	Number of Results
1975	1
2005	1
2006	7
2007	10
2008	11
2009	13
2010	29
2011	49
2012	33
2013	2
2020	1
2021	1
2022	0

1

Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via β₂-adrenoceptor.

Ouyang S, Zhang D, Zhu T, Yu S, Wunier, Hu QN, Le Y. Ouyang S, et al. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30. Toxicol In Vitro. 2021. PMID: 34601065

2

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Harding SD, Faccenda E, Southan C, Pawson AJ, Maffia P, Alexander SPH, Davenport AP, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA. Harding SD, et al. Immunology. 2020 May;160(1):10-23. doi: 10.1111/imm.13175. Epub 2020 Mar 2. Immunology. 2020. PMID: 32020584 Free PMC article. Review.

3

Emerging Therapeutic Options for the Management of COPD.

Reid DJ, Pham NT. Reid DJ, et al. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. Clin Med Insights Circ Respir Pulm Med. 2013. PMID: 23641160 Free PMC article.

4

Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.

To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B. To Y, et al. Respir Med. 2012 Dec;106(12):1715-21. doi: 10.1016/j.rmed.2012.09.002. Epub 2012 Oct 5. Respir Med. 2012. PMID: 23040786 Free article. Clinical Trial.

5

Indacaterol therapy in patients with COPD not receiving other maintenance treatment.

Decramer M, Rossi A, Lawrence D, McBryan D. Decramer M, et al. Respir Med. 2012 Dec;106(12):1706-14. doi: 10.1016/j.rmed.2012.08.022. Epub 2012 Sep 29. Respir Med. 2012. PMID: 23031496 Free article. Review.

6

Comment on the report "limitations of model-based dose selection for indacaterol in patients with chronic obstructive pulmonary disease".

Looby M, Renard D, Wright A, Morris D, Stanski D. Looby M, et al. Int J Clin Pharmacol Ther. 2012 Sep;50(9):631-7; discussion 638. doi: 10.5414/cp201758a. Int J Clin Pharmacol Ther. 2012. PMID: 22981144 No abstract available.

7

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Chong J, Karner C, Poole P. Chong J, et al. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009157. doi: 10.1002/14651858.CD009157.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972134 Free PMC article. Review.

8

An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.

Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D, Rosethorne EM, Sandham DA, Sykes DA, Trifilieff A, Turner KL, Wissler E. Beattie D, et al. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6280-5. doi: 10.1016/j.bmcl.2012.07.096. Epub 2012 Aug 4. Bioorg Med Chem Lett. 2012. PMID: 22932315

9

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.

Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP. Cope S, et al. Int J Chron Obstruct Pulmon Dis. 2012;7:415-20. doi: 10.2147/COPD.S31526. Epub 2012 Jul 5. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22848154 Free PMC article.

10

Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.

Mroz RM, Minarowski L, Chyczewska E. Mroz RM, et al. Adv Exp Med Biol. 2013;756:23-8. doi: 10.1007/978-94-007-4549-0_4. Adv Exp Med Biol. 2013. PMID: 22836615 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed